Sep 2026· Journal of Thoracic Oncology· Vol 21 9, pp.
103957
· 0 citations· 217 references
Medicine
TL;DR
This review will highlight key breakthroughs, clinical integration, limitations, and future directions related to immunotherapy for lung cancer.
Abstract
The transition from cytotoxic therapy to the use of treatment to harness the immune system in lung cancer has transformed the biology of the disease leading to prolonged survival. The understanding of tumor immunology and antigen presentation have enabled the development of immune checkpoint inhibition as monotherapy and in combinations across all stages of disease. Improvements in outcomes for patients have established immunotherapy as a cornerstone of lung cancer treatment. This review will highlight key breakthroughs, clinical integration, limitations, and future directions related to immunotherapy for lung cancer.
Current active clinical trials evaluate new immune checkpoints, including lymphocyte activation gene 3, T cell immunoreceptor with Ig and ITIM domains, and killer Ig-like receptor 2DL1/2L3.
S. Schokrpur, M. G. White, C. Roland et al.· Hematology/Oncology Clinics...· 0 citations
Immunotherapy has transformed the management of several extracranial malignancies; however, its efficacy in GBM has been limited. Large clinical trials evaluating immune checkpoint inhibitors have failed to demonstrate meaningful survival benefit in newly diagnosed and recurrent GBM. Other modalities, including dendrit...
Osama Salar, Mehar Masroor, K. Chaudhary et al.· JOURNAL OF PAKISTAN MEDICAL...· 0 citations
This review summarizes the main immunotherapeutic approaches currently investigated, including immune checkpoint inhibitors, CAR-T cell therapy, cancer vaccines, and oncolytic viruses, and examines the key biological factors responsible for treatment resistance.
D. Slavkov, S. Troyanova-Slavkova· Cancer Immunology Connect· 0 citations
Simple Summary In patients with advanced lung cancer harboring targetable gene mutations, sequential immunotherapy-targeted therapy was associated with higher rate of adverse events. A short delay between last immunotherapy administration and targeted therapy administration may increase the risk of serious adverse even...
Thomas Pierret, J. Auliac, C. Ricordel et al.· Current Oncology· 0 citations
Immunotherapy has produced a revolution in the treatment of cancer. It involves manipulating the patient's immune system to identify and destroy malignant cells. There has been an explosion in the development of these therapies in recent decades, with the emergence of monoclonal and bispecific antibodies, immune checkp...
María Verónica Nievas, A. García-Roche, Maricela Jiménez-López et al.· Medicina Intensiva· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
